These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1312 related articles for article (PubMed ID: 33536425)

  • 1. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
    Huang Q; Ji K; Tian S; Wang F; Huang B; Tong Z; Tan S; Hao J; Wang Q; Tan W; Gao GF; Yan J
    Nat Commun; 2021 Feb; 12(1):776. PubMed ID: 33536425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium.
    Marcos-Villar L; Perdiguero B; López-Bravo M; Zamora C; Sin L; Álvarez E; Sorzano CÓS; Sánchez-Cordón PJ; Casasnovas JM; Astorgano D; García-Arriaza J; Anthiya S; Borrajo ML; Lou G; Cuesta B; Franceschini L; Gelpí JL; Thielemans K; Sisteré-Oró M; Meyerhans A; García F; Esteban I; López-Bigas N; Plana M; Alonso MJ; Esteban M; Gómez CE
    Emerg Microbes Infect; 2024 Dec; 13(1):2387906. PubMed ID: 39087555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.
    de Alwis R; Gan ES; Chen S; Leong YS; Tan HC; Zhang SL; Yau C; Low JGH; Kalimuddin S; Matsuda D; Allen EC; Hartman P; Park KJ; Alayyoubi M; Bhaskaran H; Dukanovic A; Bao Y; Clemente B; Vega J; Roberts S; Gonzalez JA; Sablad M; Yelin R; Taylor W; Tachikawa K; Parker S; Karmali P; Davis J; Sullivan BM; Sullivan SM; Hughes SG; Chivukula P; Ooi EE
    Mol Ther; 2021 Jun; 29(6):1970-1983. PubMed ID: 33823303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.
    Ying B; Liang C-Y; Desai P; Scheaffer SM; Elbashir SM; Edwards DK; Thackray LB; Diamond MS
    J Virol; 2024 Sep; 98(9):e0057424. PubMed ID: 39194250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
    He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
    Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BNT162b vaccines protect rhesus macaques from SARS-CoV-2.
    Vogel AB; Kanevsky I; Che Y; Swanson KA; Muik A; Vormehr M; Kranz LM; Walzer KC; Hein S; Güler A; Loschko J; Maddur MS; Ota-Setlik A; Tompkins K; Cole J; Lui BG; Ziegenhals T; Plaschke A; Eisel D; Dany SC; Fesser S; Erbar S; Bates F; Schneider D; Jesionek B; Sänger B; Wallisch AK; Feuchter Y; Junginger H; Krumm SA; Heinen AP; Adams-Quack P; Schlereth J; Schille S; Kröner C; de la Caridad Güimil Garcia R; Hiller T; Fischer L; Sellers RS; Choudhary S; Gonzalez O; Vascotto F; Gutman MR; Fontenot JA; Hall-Ursone S; Brasky K; Griffor MC; Han S; Su AAH; Lees JA; Nedoma NL; Mashalidis EH; Sahasrabudhe PV; Tan CY; Pavliakova D; Singh G; Fontes-Garfias C; Pride M; Scully IL; Ciolino T; Obregon J; Gazi M; Carrion R; Alfson KJ; Kalina WV; Kaushal D; Shi PY; Klamp T; Rosenbaum C; Kuhn AN; Türeci Ö; Dormitzer PR; Jansen KU; Sahin U
    Nature; 2021 Apr; 592(7853):283-289. PubMed ID: 33524990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Corzo C; Noriega MA; Sánchez-Cordón PJ; Labiod N; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2024; 15():1420304. PubMed ID: 39267752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Simplified SARS-CoV-2 Mouse Model Demonstrates Protection by an Oral Replicon-Based mRNA Vaccine.
    Jawalagatti V; Kirthika P; Hewawaduge C; Park JY; Yang MS; Oh B; So MY; Kim B; Lee JH
    Front Immunol; 2022; 13():811802. PubMed ID: 35250985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
    Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
    Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
    Tian JH; Patel N; Haupt R; Zhou H; Weston S; Hammond H; Logue J; Portnoff AD; Norton J; Guebre-Xabier M; Zhou B; Jacobson K; Maciejewski S; Khatoon R; Wisniewska M; Moffitt W; Kluepfel-Stahl S; Ekechukwu B; Papin J; Boddapati S; Jason Wong C; Piedra PA; Frieman MB; Massare MJ; Fries L; Bengtsson KL; Stertman L; Ellingsworth L; Glenn G; Smith G
    Nat Commun; 2021 Jan; 12(1):372. PubMed ID: 33446655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.
    Scaglione A; Opp S; Hurtado A; Lin Z; Pampeno C; Noval MG; Thannickal SA; Stapleford KA; Meruelo D
    Front Immunol; 2021; 12():719077. PubMed ID: 34394127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection.
    Li M; Guo J; Lu S; Zhou R; Shi H; Shi X; Cheng L; Liang Q; Liu H; Wang P; Wang N; Wang Y; Fu L; Xing M; Wang R; Ju B; Liu L; Lau SY; Jia W; Tong X; Yuan L; Guo Y; Qi H; Zhang Q; Huang Z; Chen H; Zhang Z; Chen Z; Peng X; Zhou D; Zhang L
    Front Immunol; 2021; 12():697074. PubMed ID: 34262569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection.
    Elia U; Rotem S; Bar-Haim E; Ramishetti S; Naidu GS; Gur D; Aftalion M; Israeli M; Bercovich-Kinori A; Alcalay R; Makdasi E; Chitlaru T; Rosenfeld R; Israely T; Melamed S; Abutbul Ionita I; Danino D; Peer D; Cohen O
    Nano Lett; 2021 Jun; 21(11):4774-4779. PubMed ID: 34032435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice.
    Sun S; He L; Zhao Z; Gu H; Fang X; Wang T; Yang X; Chen S; Deng Y; Li J; Zhao J; Li L; Li X; He P; Li G; Li H; Zhao Y; Gao C; Lang X; Wang X; Fei G; Li Y; Geng S; Gao Y; Wei W; Hu Z; Han G; Sun Y
    Cell Mol Immunol; 2021 Apr; 18(4):1070-1073. PubMed ID: 33731916
    [No Abstract]   [Full Text] [Related]  

  • 15. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
    Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2021; 12():824728. PubMed ID: 35154086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection.
    Liu R; Americo JL; Cotter CA; Earl PL; Erez N; Peng C; Moss B
    Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33688035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters.
    Zhou P; Watt J; Mai J; Cao H; Li Z; Chen Z; Duan R; Quan Y; Gingras AC; Rini JM; Hu J; Liu J
    Front Immunol; 2024; 15():1430928. PubMed ID: 39281669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
    Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
    Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.